These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7532936)

  • 1. Clozapine therapy and increases in homovanillic acid.
    Risch SC
    Arch Gen Psychiatry; 1995 Mar; 52(3):244. PubMed ID: 7532936
    [No Abstract]   [Full Text] [Related]  

  • 2. Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication.
    Risch SC; Lewine RR
    Arch Gen Psychiatry; 1993 Aug; 50(8):670. PubMed ID: 7688212
    [No Abstract]   [Full Text] [Related]  

  • 3. The dopamine-serotonin relationship in clozapine response.
    Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
    Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
    Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man.
    Ackenheil M; Beckmann H; Greil W; Hoffmann G; Markianos E; Raese J
    Adv Biochem Psychopharmacol; 1974; 9(0):647-57. PubMed ID: 4836227
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of clozapine response in schizophrenia.
    Pickar D; Owen RR; Litman RE; Hsiao JK; Su TP
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():129-32. PubMed ID: 7525541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central dopamine turnover in schizophrenic syndromes.
    Bowers MB
    Arch Gen Psychiatry; 1974 Jul; 31(1):50-4. PubMed ID: 4835986
    [No Abstract]   [Full Text] [Related]  

  • 9. Are monoamine metabolites in cerebrospinal fluid worth measuring?
    Potter WZ; Manji HK
    Arch Gen Psychiatry; 1993 Aug; 50(8):653-6. PubMed ID: 7688211
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-function relations in schizophrenia: brain morphology and neuropsychology.
    Bilder RM
    Prog Exp Pers Psychopathol Res; 1992; 15():183-251. PubMed ID: 1285281
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis.
    Goodwin FK; Post RM
    Res Publ Assoc Res Nerv Ment Dis; 1975; 54():299-332. PubMed ID: 769117
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.
    Scheepers FE; Gispen-de Wied CC; Westenberg HG; Kahn RS
    Neuropsychopharmacology; 2001 Oct; 25(4):468-75. PubMed ID: 11557160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.
    van Kammen DP; Peters J; van Kammen WB
    Psychiatr Clin North Am; 1986 Mar; 9(1):81-97. PubMed ID: 2421272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous quantification of homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid by mass fragmentography.
    Fri CG; Wiesel FA; Sedvall G
    Life Sci; 1974 Jun; 14(12):2469-80. PubMed ID: 4549970
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal fluid probenecid studies: a reinterpretation.
    Cowdry RW; Ebert MH; van Kammen DP; Post RM; Goodwin FK
    Biol Psychiatry; 1983 Nov; 18(11):1287-99. PubMed ID: 6197100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid amine metabolites in acute schizophrenia.
    Post RM; Fink E; Carpenter WT; Goodwin FK
    Arch Gen Psychiatry; 1975 Aug; 32(8):1063-9. PubMed ID: 1156113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics.
    Carlsson A; Roos BE; Wålinder J; Skott A
    J Neural Transm; 1973; 34(2):125-32. PubMed ID: 4146641
    [No Abstract]   [Full Text] [Related]  

  • 18. Clozapine pharmacology and tardive dyskinesia.
    Lieberman J; Johns C; Cooper T; Pollack S; Kane J
    Psychopharmacology (Berl); 1989; 99 Suppl():S54-9. PubMed ID: 2479047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites.
    Bowers MB; Heninger GR
    Commun Psychopharmacol; 1977; 1(2):135-45. PubMed ID: 603996
    [No Abstract]   [Full Text] [Related]  

  • 20. CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.
    Kirstein L; Bowers MB; Heninger G
    Biol Psychiatry; 1976 Aug; 11(4):421-34. PubMed ID: 963133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.